

Pfizer Independent Medical Education RFP

Improving Treatment Environment and Survivorship for Multiple Myeloma

Competitive Grant Program –Pfizer Internal Review Process

Overview

This application is for medical educational projects for healthcare professionals that accelerate the improvement of treatment environments for multiple myeloma patients regarding diagnosis, treatment, comprehensive care and social support.

Geographic Scope

Japan

Project Types and Area of Interest

The target disease is hematologic malignancy (multiple myeloma).

The purpose of this application is for Pfizer to provide support for a medical educational project for healthcare professionals that accelerates an improved therapeutic environment for the diagnosis, treatment, comprehensive care, and social support of patients with multiple myeloma.

Key Milestones

- Application submission deadline: *June 30, 2023*
- Anticipated decision notification date: August 31, 2023
- Anticipated project start date: November 1, 2023

Funding Range and Project Length

Individual projects requesting up to 7,000,000 JPY will be considered.

Anticipated Projects Start and End Dates: November 2023 – March 2026

Note this RFP is also available in [Japanese](#) for your convenience

I. Eligibility

Geographic Scope:

- Japan

Applicant Eligibility Criteria

- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit, the requesting organization must be accredited.

II. Requirements

Date RFP Issued

- February 22, 2023

Clinical Area

- Oncology-Hematology-Myeloma

General Area of Interest for this RFP:

The treatment of multiple myeloma has improved with the advent of novel agents, including molecular-targeted agents and antibody drugs, and patient prognosis has improved significantly with promise of long-term survival^{1, 2}). On the other hand, information and support regarding the significance and economic impact of treatment methods tailored to each patient's condition and environment is still insufficient, and the support system needs to be updated according to the latest findings³⁻⁵). Pfizer will support educational projects that will lead to improved treatment environments and survivorship for patients with multiple myeloma considering these recent changes in multiple myeloma treatment and medical needs.

Areas of interest for this RFP include but are not limited to:

- Educational projects to accelerate governmental and community health care support for older patients and their families
- Educational projects to accelerate understanding of diseases and treatments for older patients
- Educational projects for healthcare professionals to accelerate methods to alleviate anxiety related to bone lesions and organ damage in patients, which may limit their daily life and social activities
- Educational activities using various data sources available in Japan and real-world clinical data to accelerate understanding of the current status of multiple myeloma treatment in Japan
- Educational projects to provide patients and their families with easy-to-understand information on the mechanism of action of multiple myeloma drugs, the benefits and risks of treatment, and the cost burden of treatment

Educational projects can be considered in the form of events, satellite symposia, hands-on seminars, workshops, online courses, printed materials, digital tools and so on.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. In addition, it is not also our intent to support guideline development (e.g., clinical treatment guidelines) from the viewpoint of COI.

Target Audience

- Physicians, nurses, pharmacists, clinical laboratory technologists and other health care professionals involved in testing, diagnosis, treatment, comprehensive care, and social support for patients with multiple myeloma.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to 7,000,000 JPY will be considered.

Key Dates:

- RFP release date: 2/22/2023
- Grant Application due date: 6/30/2023
 - Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: 8/31/2023
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: 11/1/2023 to 3/31/2026

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to https://www.cybergrants.com/pls/cybergrants/ao_login and sign in.
- First-time users should click “Create your password”.
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
 - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
 - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
- Select the following Competitive Grant Program Name: “2023 ONC JP: Improving Treatment Environment and Survivorship for Multiple Myeloma”
 - Select the following Primary Area of Interest: “Oncology – Hematology”
- Requirements for submission:
 - Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, MEG-J Office, Pfizer Japan Inc. (meg.japan@pfizer.com), with the subject line “Improving Treatment Environment and Survivorship for Multiple Myeloma”.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
 - Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References

1. Masahiro Kizaki, Nihon Naika Gakkai Zasshi, 2021 Volume 110 Issue Suppl Pages 115a
2. Chiaki Nakaseko, Nihon Naika Gakkai Zasshi, 2020 Volume 109 Issue 5 Pages 987-994
3. Kei Hirai, Asayo Yamamura, Nanami Suzuki, Asao Ogawa, Palliative Care Research, 2021 Volume 16 Issue 1 Pages 27-34
4. Kumiko Morita, J. Jpn. Soc. Cancer Nurs., 2021 Volume 35 Article ID: 35_322_morita
5. American Cancer Society <https://www.cancer.org/cancer/multiple-myeloma/treating/by-stage.html>

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Project title, date created, and version number should be described on the front page. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application
- While estimating your budget please keep the following items in mind:
 - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
 - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details.